Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JANUMET vs DEXEDRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Sitagliptin is primarily excreted unchanged in urine via active tubular secretion, with minor metabolism via CYP3A4 and CYP2C8. Metformin is not metabolized and is excreted unchanged in urine by tubular secretion.
Primarily metabolized by CYP2D6 to 4-hydroxydextroamphetamine, which is further metabolized to various metabolites. Also undergoes deamination and oxidation.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Sitagliptin: 38% (albumin). Metformin: negligible (<5%).
Approximately 16-20% bound; primarily to albumin
Sitagliptin: 198 L (≈2.8 L/kg for 70 kg). Metformin: 654 L (≈9.3 L/kg for 70 kg). Clinical meaning: Metformin Vd indicates extensive tissue distribution, predominantly in gastrointestinal tissues and red blood cells.
3.5-4.5 L/kg; indicates extensive tissue distribution, particularly CNS
Sitagliptin: 87% (oral). Metformin: 50-60% (oral), variable with food.
Oral: 75-100% (immediate-release), 70-90% (extended-release); rectal and parenteral routes are not clinically utilized
Contraindicated if e GFR <30 m L/min/1.73 m2. e GFR 30-45: do not initiate; if already on therapy, reduce dose to 25 mg sitagliptin/500 mg metformin once daily. e GFR 45-60: maximum dose 50 mg sitagliptin/1000 mg metformin twice daily. Monitor renal function.
GFR 15–30 m L/min: use with caution, consider dose reduction by 50%. GFR <15 m L/min: not recommended.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component risk of lactic acidosis.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Age 3–5 years: 2.5 mg orally once daily, increase by 2.5 mg weekly as needed (max 40 mg/day). Age ≥6 years: 5 mg orally once or twice daily, increase by 5 mg weekly (max 40 mg/day).
Use with caution; monitor renal function closely. Initiate at lowest dose (25 mg sitagliptin/500 mg metformin) and titrate slowly. Avoid in patients aged ≥80 years unless normal renal function confirmed.
Start at lowest dose (2.5–5 mg orally once daily), titrate slowly; monitor for cardiovascular effects, agitation, and weight loss.
Lactic acidosis: Metformin hydrochloride can cause lactic acidosis, a rare but serious condition. If suspected, discontinue Janumet and treat promptly.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including DEXEDRINE, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Lactic acidosis risk (sepsis, dehydration, hepatic impairment, alcohol abuse, unstable CHF, radiologic contrast studies),Pancreatitis (discontinue if suspected),Hypoglycemia (especially with sulfonylurea or insulin coadministration),Renal impairment (assess renal function before initiation and periodically; contraindicated if e GFR <30 m L/min/1.73 m²),Vitamin B12 deficiency (monitor levels with long-term metformin use),Hypersensitivity reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome),Heart failure (monitor for signs; cardiovascular outcome trials showed no increased risk with saxagliptin, but caution with DPP-4 inhibitors)
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, manic episodes, and aggression,Seizures in patients with prior seizure history,Long-term suppression of growth in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when co-administered with serotonergic drugs
Severe renal impairment (e GFR <30 m L/min/1.73 m²),Acute or chronic metabolic acidosis (including diabetic ketoacidosis),History of serious hypersensitivity reaction to Janumet or its components,Use of iodinated contrast agents with e GFR <60 m L/min/1.73 m² or liver disease, alcohol abuse, or conditions altering renal function
Known hypersensitivity to amphetamine products or other components of DEXEDRINE,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis),Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Avoid excessive alcohol intake (increases risk of lactic acidosis). Take with food to minimize gastrointestinal upset. No specific food restrictions; maintain consistent carbohydrate intake for blood glucose control.
Avoid high-fat meals with immediate-release formulations as they may delay absorption; for extended-release, high-fat meals can increase peak concentration. Acidic foods (e.g., citrus fruits, fruit juices, carbonated drinks) can reduce absorption. Avoid excessive caffeine (coffee, tea, energy drinks) as it may exacerbate central nervous system stimulation and cardiovascular effects. Maintain adequate hydration. Grapefruit and other CYP2D6 inhibitors may increase effects.
Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there are no adequate well-controlled studies in pregnant women. Risk cannot be ruled out. Metformin crosses the placenta and may cause fetal lactic acidosis in third trimester. Generally, insulin is preferred for gestational diabetes management.
First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (hyperactivity, irritability, feeding difficulties). Dextroamphetamine is a sympathomimetic amine with potential for vasoconstriction reducing uteroplacental perfusion.
Sitagliptin is excreted in rat milk; unknown in humans. Metformin is excreted into human milk at low levels with an estimated infant dose of 0.18-0.4 mg/kg/day (M/P ratio ~0.35-0.65). Due to potential for hypoglycemia and uncertain long-term effects, breastfeeding is not recommended during Janumet therapy.
Dextroamphetamine is excreted into breast milk; M/P ratio not established but concentration about 2-7 times maternal plasma. potential for infant stimulation, insomnia, and growth impairment. American Academy of Pediatrics recommends use during breastfeeding only if benefits outweigh risks; monitor infant for agitation and poor weight gain.
Janumet is not recommended during pregnancy. If used, dose adjustments may be necessary due to pregnancy-induced increased renal clearance of metformin; however, no specific guidelines exist. Renal function should be monitored closely to avoid metformin accumulation and lactic acidosis. Typically, insulin therapy is initiated.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and enhanced renal clearance may reduce serum concentrations of dextroamphetamine. Dose adjustment may be necessary based on clinical response; start with lowest effective dose and monitor for worsening ADHD symptoms. Avoid in severe hypertension or preeclampsia.
Janumet combines sitagliptin (DPP-4 inhibitor) and metformin (biguanide). Dose adjustment required for renal impairment (e GFR <45 m L/min/1.73 m² contraindicated; <30 for metformin component). Monitor for lactic acidosis (rare but serious) especially in hypoxic states. Discontinue for 48 hours before iodinated contrast imaging with metformin component. Pancreatitis risk: monitor for persistent severe abdominal pain. Not for type 1 diabetes or ketoacidosis.
Monitor for hypertension, tachycardia, and mental status changes (psychosis, mania) especially at high doses. Avoid late-day dosing to prevent insomnia. Use with caution in patients with pre-existing cardiovascular disease or hyperthyroidism. Dextroamphetamine can suppress appetite and cause weight loss; monitor growth in children. Abuse potential is high; schedule II controlled substance. Can precipitate tics in susceptible individuals. Contraindicated within 14 days of MAOIs due to hypertensive crisis.
Take with meals to reduce gastrointestinal side effects.,If you miss a dose, take it with your next meal unless the next dose is due; do not double dose.,Monitor for symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) and report immediately.,Report symptoms of lactic acidosis (muscle pain, weakness, difficulty breathing, drowsiness) especially if you have kidney problems or are over 65.,Avoid alcohol while taking this medication to reduce the risk of lactic acidosis.,Stay hydrated, especially if you are sick (vomiting, diarrhea) or exercising intensely.,Check blood sugar regularly as directed; carry a source of sugar for hypoglycemia.,Tell your doctor if you are pregnant, breastfeeding, or planning surgery.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew the extended-release capsules; swallow whole.,Avoid taking the medication in the evening or close to bedtime to prevent trouble sleeping.,Report any chest pain, shortness of breath, fainting, or rapid heart rate to your doctor immediately.,Contact your doctor if you experience new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,You may experience decreased appetite and weight loss; maintain a healthy diet and inform your doctor if weight loss is significant.,Do not stop taking abruptly; taper dose under medical supervision to avoid withdrawal symptoms.,This medication has potential for abuse and dependence; keep in a safe place and do not share with others.,Avoid alcohol and caffeine as they may increase side effects like jitteriness and heart palpitations.,Tell all healthcare providers you are taking this medication, especially before surgery or dental procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JANUMET vs DEXEDRINE, answered by our medical review team.
JANUMET is a DPP-4 Inhibitor/Biguanide Combination that works by Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.. DEXEDRINE is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JANUMET and DEXEDRINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JANUMET is: Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.. The standard adult dose of DEXEDRINE is: 5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JANUMET and DEXEDRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JANUMET is classified as Category C. Janumet (sitagliptin/metformin) is classified as FDA Pregnancy Category B for sitagliptin and Category B for metformin. Animal studies show no evidence of teratogenicity, but there. DEXEDRINE is classified as Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of pr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.